TS-1

luvmum
luvmum Member Posts: 457 Member
in Colorectal Cancer #1
Dear all,

My mum had severe allergy from oxaliplatin (anyway her CEA rose after oxaliplatin!) and her onc decided to change to TS-1 (oral drug which is similar to xeloda and have similar effect of 5-FU).

Have you anyone of you had heard of it and tried it before?

Thanks a lot and hope you are all well!
Hugs Dora

Comments

  • have2believe
    have2believe Member Posts: 134
    #2
    didn't know it was available
    I've heard good things about this drug, especially in South Korea, Japan. I didn't know it was available in the US. For whatever reason, in some parts of the world, the response is better (eastern v. western). http://www.hemonctoday.com/article.aspx?rid=88872
  • tanstaafl
    tanstaafl Member Posts: 1,313 Member
    #3
    have2believe said:

    didn't know it was available
    I've heard good things about this drug, especially in South Korea, Japan. I didn't know it was available in the US. For whatever reason, in some parts of the world, the response is better (eastern v. western). http://www.hemonctoday.com/article.aspx?rid=88872

    EU / UK
    Europe seems more interested, or less economically conflicted, than the FDA.
  • tanstaafl
    tanstaafl Member Posts: 1,313 Member
    #4
    our investigation
    This past year oral TS-1 was considered for my wife as a potential backup 5FU treatment for tumor masses if her nodes were inoperable. TS-1 and UFT both use the same active molecule, tegafur, with added secondary molecules that are DPD inhibitors. DPD inhibition reduces the amount of 5FU needed to more selectively treat cancer.

    UFT, Xeloda, TS-1
    TS-1 was successfully developed in Japan as a more penetrating 5FU drug for treating gastric cancers, often more refractory than metastatic colon cancer. However, TS-1 alone had not performed quite so outstandingly well for metastatic colon cancer. TS-1, dosed about 60-100 mg of tegafur per day, simply delivers less tegafur than UFT, typically dosed at 300-600 mg of tegafur per day, hence less THF metabolite. Also I finally found a statement that the gimeracil/oteracil DPD package interfered with tegafur breakdown in a way that prevented formation of tegafur's THF derivatives which have preclinical evidence of function as HIF-1 inhibitors. HIF-1, hypoxia inducible factor 1 (formerly HIF), is a very important molecular cancer target with no officially approved treatment.

    My wife takes UFT with no PET active tumor masses (CIM-UFT-LV-PSK). She has stated that UFT actually makes her feel better, which can be interpreted as a possible side effect (benefit) of gamma hydroxybutyrate, the low dose THF metabolite. UFT may be best for continuous "birth control" of isolated bloodborne clusters without active tumor masses. So we decided to prefer daily UFT without known tumor activity for mop up and maintenance.

    During the earlier "no-surgery standoff" and after discussion with one of our doctors, we decided that if my wife was inoperable we would consider either Xeloda or TS-1 for more node penetration, along with a replacement dose of oxybate (gamma hydroxybutyrate, off label) for HIF inhibition, along with the other immune (like PSK, vit D3) and molecular target agents (off label like cimetidine, and advanced nutrients) that she has been prescribed.

    Since she had a successful surgery for the para aortic nodes, she is not using Xeloda or TS-1, hopefully will never "have to". It may depend on the "lung thingies", these thoughts represent our TS-1 investigation to date.
  • have2believe
    have2believe Member Posts: 134
    #5
    tanstaafl said:

    our investigation
    This past year oral TS-1 was considered for my wife as a potential backup 5FU treatment for tumor masses if her nodes were inoperable. TS-1 and UFT both use the same active molecule, tegafur, with added secondary molecules that are DPD inhibitors. DPD inhibition reduces the amount of 5FU needed to more selectively treat cancer.

    UFT, Xeloda, TS-1
    TS-1 was successfully developed in Japan as a more penetrating 5FU drug for treating gastric cancers, often more refractory than metastatic colon cancer. However, TS-1 alone had not performed quite so outstandingly well for metastatic colon cancer. TS-1, dosed about 60-100 mg of tegafur per day, simply delivers less tegafur than UFT, typically dosed at 300-600 mg of tegafur per day, hence less THF metabolite. Also I finally found a statement that the gimeracil/oteracil DPD package interfered with tegafur breakdown in a way that prevented formation of tegafur's THF derivatives which have preclinical evidence of function as HIF-1 inhibitors. HIF-1, hypoxia inducible factor 1 (formerly HIF), is a very important molecular cancer target with no officially approved treatment.

    My wife takes UFT with no PET active tumor masses (CIM-UFT-LV-PSK). She has stated that UFT actually makes her feel better, which can be interpreted as a possible side effect (benefit) of gamma hydroxybutyrate, the low dose THF metabolite. UFT may be best for continuous "birth control" of isolated bloodborne clusters without active tumor masses. So we decided to prefer daily UFT without known tumor activity for mop up and maintenance.

    During the earlier "no-surgery standoff" and after discussion with one of our doctors, we decided that if my wife was inoperable we would consider either Xeloda or TS-1 for more node penetration, along with a replacement dose of oxybate (gamma hydroxybutyrate, off label) for HIF inhibition, along with the other immune (like PSK, vit D3) and molecular target agents (off label like cimetidine, and advanced nutrients) that she has been prescribed.

    Since she had a successful surgery for the para aortic nodes, she is not using Xeloda or TS-1, hopefully will never "have to". It may depend on the "lung thingies", these thoughts represent our TS-1 investigation to date.

    interesting research
    Are you in the UK or outside the US, and it's available there? It's good to hear that there are other drugs out there, and interesting to learn about differences in response based on demographics. It's also a bit scary knowing that one part of the world may use a particular drug because of its efficacy there, but the data isn't as strong somewhere else. However, that person living somewhere else may really benefit from it.
  • tanstaafl
    tanstaafl Member Posts: 1,313 Member
    #6
    have2believe said:

    interesting research
    Are you in the UK or outside the US, and it's available there? It's good to hear that there are other drugs out there, and interesting to learn about differences in response based on demographics. It's also a bit scary knowing that one part of the world may use a particular drug because of its efficacy there, but the data isn't as strong somewhere else. However, that person living somewhere else may really benefit from it.

    thanks
    UFT is commonly available outside the US. Last I checked TS-1 seemed to be in some of the more highly developed countries.

    I don't think demographics has much to do with it. Mostly politics, policies, trade and market issues. I stated what we're doing or deciding, fusing others' research and results, discussing our results, and what materials were available. This is not based on any *single* established protocol or recommendation.

    If one were stuck with the US only, one could make do with capecitabine, which should soon be a generic, too. The off label chemistry and supplements were the hardest to aggregate.

Discussion Boards